ELEV (Elevation Oncology) Forward P/E Multiple
The expected P/E multiple for Elevation Oncology (ELEV) reflects revenue volatility from grants and investments in targeted therapy. This trend is driven by a virtual development model utilizing third-party laboratories and the search for global distribution partners. The indicator's fluctuations on this chart highlight shifting market cycles, while 0.00 serves as the final marker for the current corporate valuation level.
Summary analytical data breakdowns for Elevation Oncology, Inc. (ELEV)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Elevation Oncology|ELEV - Long-Term Liabilities to Capital|Short-Term Debt to Capital Elevation Oncology Inc.|ELEV - Company Cumulative Debt|Debt to Book Capitalization Ratio Elevation Oncology, Inc.|ELEV - Company Long-Term Debt|Company Short-Term Debts Elevation Oncology|Quick Liquidity Indicator elevationoncology.com
- financial results and valuation multiples details:
ELEV - Company Net Income|Projected Future Earnings Elevation Oncology|ELEV - P/E Multiple|Projected Price to Earnings Elevation Oncology|ELEV - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Elevation Oncology, Inc.|ELEV - Operating income before deduction of amortization|Earnings per share for the last twelve months Elevation Oncology|ELEV - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months elevationoncology.com|ELEV - Earnings per share growth this year|Expected earnings per share growth for next year Elevation Oncology
- sales volume and revenue indicators:
Analysis of all company metrics:ELEV Elevation Oncology, Inc.
For Elevation Oncology (ELEV), whose operations focus on developing targeted therapies with minimal environmental impact, the company's forward P/E multiple serves as an indicator of market expectations for future success. This metric correlates current market capitalization with expected net income, allowing investors to assess the cost of one dollar of future earnings and determine the risk of overpayment or the likelihood of long-term asset stagnation.
Competing companies
Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|Xenetic Bio - Forward P/E Multiple|SLRX - Forward P/E Multiple|PPBT: Forward P/E Multiple|Price to Future Earnings Ratio AONC|BGNE (BeiGene Ltd) - Forward P/E Multiple|CKPT (Checkpoint Therapeutics, Inc) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple
